Hypoglycaemia may be more common in GLP-1A toxicity than has been suggested by NPIS
Insbesondere fettlsliche Giftstoffe werden hier zunchst unschdlich gemacht und zu einem wasserlslichen Stoff umgebaut, um sie anschlieend auszuscheiden
This phenomenon occurs through several metabolic mechanisms: Increased breakdown of purines : When the body metabolises fat and muscle tissue during weight loss, purines (compounds found in body tissues) are broken down, producing uric acid as a by-product Ketone body production : Rapid weight loss, particularly with very low-calorie diets, leads to ketone production, which competes with uric acid for excretion by the kidneys Reduced renal clearance : Ketones and other metabolic by-products can temporarily impair the kidneys' ability to excrete uric acid efficiently Dehydration : Weight loss programmes may involve reduced fluid intake or increased fluid loss, concentrating uric acid in the blood The rate of weight loss appears to be a critical factor
It is consistent, predictable, and reassuring once you know what causes it
This cardiovascular protective effect is something other GLP-1 medications have not yet demonstrated at the same level, making Wegovy widely regarded by clinicians as the current gold-standard option specifically for obesity with cardiovascular risk